Te biochemical complexity of the endocannabinoid system with some remarks on stress and related disorders: A minireview

Endocrine Regulations

Volumn 46, Issue 2, 2012, Pages 107-124

  Barna, I ^a   Zelena, D ^a  

^a INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

2 AG; Anandamide; FAAH; MAGL; PPAR ; TPRV1

Indexed keywords

ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CORTICOSTERONE; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; DIACYLGLYCEROL; ENDOCANNABINOID; FATTY ACID AMIDASE; G PROTEIN COUPLED RECEPTOR; JZL184; N (4 HYDROXYPHENYL) ARACHIDONAMIDE; N (4 HYDROXYPHENYL)ARACHIDONAMIDE; NEUROTRANSMITTER; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1; CANNABINOID RECEPTOR;

ANXIETY; ARTICLE; BIOSYNTHESIS; DEGRADATION; DEPRESSION; HUMAN; HYDROLYSIS; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; NONHUMAN; OXIDATION; STRESS; ANIMAL; BRAIN LEVEL; CHEMISTRY; MENTAL STRESS; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGICAL STRESS; PHYSIOLOGY; REVIEW;

ANIMALS; BRAIN CHEMISTRY; ENDOCANNABINOIDS; HUMANS; RECEPTORS, CANNABINOID; STRESS, PHYSIOLOGICAL; STRESS, PSYCHOLOGICAL;

EID: 84875341363     PISSN: 12100668     EISSN: 13360329     Source Type: Journal    
DOI: 10.4149/endo_201202107     Document Type: Article

References (186)

1. Artmann A, Petersen G, Hellgren LI, Boberg J, Skonberg C, Nellemann C, Hansen SH, Hansen HS: Influence of dietary fatty acids on endocannabinoid and N-acylethanolamine levels in rat brain, liver and small intestine. Biochim Biophys Acta 1781, 200-212, 2008.
2. Aso E, Ozaita A, Valdizan EM, Ledent C, Pazos A, Maldonado R, Valverde O: BDNF impairment in the hippocampus is related to enhanced despair behavior in CB1 knockout mice. J Neurochem 105, 565-572, 2008. http://dx.doi. org/10.1111/j.1471-4159.2007.05149.x
3. Astarita G, Ahmed F, Piomelli D: Lipidomic analysis of biological samples by liquid chromatography coupled to mass spectrometry. Methods Mol Biol 579, 201-219, 2009. http://dx.doi.org/10.1007/978-1-60761-322-0_10
4. Bains RK, Wells SE, Flavell DM, Fairhall KM, Strom M, Le Tissier P, Robinson IC: Visceral obesity without insulin resistance in late-onset obesity rats. Endocrinology 145, 2666-2679, 2004. http://dx.doi.org/10.1210/en.2003-1608
5. Baker D, Pryce G, Davies WL, Hiley CR: In silico patent searching reveals a new cannabinoid receptor. Trends Pharmacol Sci 27, 1-4, 2006. http://dx.doi.org/10.1016/j.tips.2005.11.003
6. Balvers MG, Verhoeckx KC, Witkamp RF: Development and validation of a quantitative method for the determination of 12 endocannabinoids and related compounds in human plasma using liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 877, 1583-1590, 2009. http://dx.doi.org/10.1016/j. jchromb.2009.04.010
7. Barna I, Zelena D, Arszovszki AC, Ledent C: Te role of endogenous cannabinoids in the hypothalamo-pituitary-adrenal axis regulation: in vivo and in vitro studies in CB1 receptor knockout mice. Life Sci 75, 2959-2970, 2004. http:// dx.doi.org/10.1016/j.lfs.2004.06.006
8. Begg M, Pacher P, Batkai S, Osei-Hyiaman D, Ofertaler L, Mo FM, Liu J, Kunos G: Evidence for novel cannabinoid receptors. Pharmacol Ter 106, 133-145, 2005. http://dx.doi.org/10.1016/j.pharmthera.2004.11.005
9. Beltramo M, Stella N, Calignano A, Lin SY, Makriyannis A, Piomelli D: Functional role of high-afnity anandamide transport, as revealed by selective inhibition. Science 277, 1094-1097, 1997. http://dx.doi.org/10.1126/science.277.5329.1094
10. Benazzi F: Depression induced by orlistat (Xenical). Can J Psychiatry 45, 87, 2000.
11. Berger A, Crozier G, Bisogno T, Cavaliere P, Innis S, Di Marzo V: Anandamide and diet: inclusion of dietary arachidonate and docosahexaenoate leads to increased brain levels of the corresponding N-acylethanolamines in piglets. Proc Natl Acad Sci U S A 98, 6402-6406, 2001. http://dx.doi.org/10.1073/pnas.101119098
12. Bitencourt RM, Pamplona FA, Takahashi RN: Facilitation of contextual fear memory extinction and anti-anxiogenic effects of AM404 and cannabidiol in conditioned rats. Eur Neuropsychopharmacol 18, 849-859, 2008. http:// dx.doi.org/10.1016/j.euroneuro.2008.07.001
13. Blankman JL, Simon GM, Cravatt BF: A comprehensive profle of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem Biol 14, 1347-1356, 2007. http://dx.doi.org/10.1016/j.chembiol.2007.11.006
14. Breese GR, Knapp DJ, Overstreet DH, Navarro M, Wills TA, Angel RA: Repeated lipopolysaccharide (LPS) or cytokine treatments sensitize ethanol withdrawal-induced anxiety-like behavior. Neuropsychopharmacology 33, 867-876, 2008. http://dx.doi.org/10.1038/sj.npp.1301468
15. Bruinsma K, Taren DL: Chocolate: food or drug? J Am Diet Assoc 99, 1249-1256, 1999. http://dx.doi.org/10.1016/S00028223(99)00307-7
16. Buczynski M W, Parsons LH: Quantifcation of brain endocannabinoid levels: methods, interpretations and pitfalls. Br J Pharmacol 160, 423-442, 2010. http://dx.doi.org/10.1111/j.1476-5381.2010.00787.x
17. Busquets-Garcia A, Puighermanal E, Pastor A, de la Torre R, Maldonado R, Ozaita A: Differential role of anandamide and 2-arachidonoylglycerol in memory and anxiety-like responses. Biol Psychiatry 70, 479-486, 2011. http:// dx.doi.org/10.1016/j.biopsych.2011.04.022
18. Cabral GA, Marciano-Cabral F: Cannabinoid receptors in microglia of the central nervous system: immune functional relevance. J Leukoc Biol 78, 1192-1197, 2005. http://dx.doi.org/10.1189/jlb.0405216
19. Calignano A, La Rana G, Piomelli D: Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide. Eur J Pharmacol 419, 191-198, 2001. http://dx.doi.org/10.1016/S0014-2999(01)00988-8
20. Capasso R, Izzo AA, Fezza F, Pinto A, Capasso F, Mascolo N, Di Marzo V: Inhibitory effect of palmitoylethanolamide on gastrointestinal motility in mice. Br J Pharmacol 134, 945-950, 2001. http://dx.doi.org/10.1038/sj.bjp.0704339
21. Carr T P, Jesch ED, Brown AW: Endocannabinoids, metabolic regulation, and the role of diet. Nutr Res 28, 641-650, 2008. http://dx.doi.org/10.1016/j.nutres.2008.08.003
22. Carriba P, Ortiz O, Patkar K, Justinova Z, Stroik J, Temann A, Muller C, Woods AS, Hope BT, Ciruela F, Casado V, Canela EI, Lluis C, Goldberg SR, Moratalla R, Franco R, Ferre S: Striatal adenosine A2A and cannabinoid CB1 receptors form functional heteromeric complexes that mediate the motor effects of cannabinoids. Neuropsychopharmacology 32, 2249-2259, 2007. http://dx.doi.org/10.1038/sj.npp.1301375
23. Casarotto PC, Terzian AL, Aguiar DC, Zangrossi H, Guimaraes FS, Wotjak CT, Moreira FA: Opposing Roles for Cannabinoid Receptor Type-1 (CB(1)) and Transient Receptor Potential Vanilloid Type-1 Channel (TRPV1) on the Modulation of Panic-Like Responses in Rats. Neuropsychopharmacology 37, 478-486, 2012. http://dx.doi. org/10.1038/npp.2011.207
24. Correa F, Mestre L, Molina-Holgado E, Arevalo-Martin A, Docagne F, Romero E, Molina-Holgado F, Borrell J, Guaza C: Te role of cannabinoid system on immune modulation: therapeutic implications on CNS infammation. Mini Rev Med Chem 5, 671-675, 2005. http://dx.doi.org/10.2174/1389557054368790
25. Cota D, Marsicano G, Tschop M, Grubler Y, Flachskamm C, Schubert M, Auer D, Yassouridis A, Tone-Reineke C, Ortmann S, Tomassoni F, Cervino C, Nisoli E, Linthorst AC, Pasquali R, Lutz B, Stalla GK, Pagotto U: Te endogenous cannabinoid system afects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 112, 423-431, 2003.
26. Cravatt BF, Giang DK, Mayfeld SP, Boger DL, Lerner RA, Gilula NB: Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384, 83-87, 1996. http://dx.doi.org/10.1038/384083a0
27. Croci T, Landi M, Galzin AM, Marini P: Role of cannabinoid CB1 receptors and tumor necrosis factor-alpha in the gut and systemic anti-infammatory activity of SR 141716 (rimonabant) in rodents. Br J Pharmacol 140, 115-122, 2003. http://dx.doi.org/10.1038/sj.bjp.0705412
28. Dalle Carbonare M, Del Giudice E, Stecca A, Colavito D, Fabris M, D'Aarrigo A, Bernardini D, Dam M, Leon A: A saturated N-acylethanolamine other than N-palmitoyl ethanolamine with anti-infammatory properties: a neglected story. J Neuroendocrinol 20 Suppl 1, 26-34, 2008. http://dx.doi.org/10.1111/j.1365-2826.2008.01689.x
29. Dalton GD, Bass CE, Van Horn CG, Howlett AC: Signal transduction via cannabinoid receptors. CNS Neurol Disord Drug Targets 8, 422-431, 2009.
30. De Petrocellis L, Cascio MG, Di Marzo V: Te endocannabinoid system: a general view and latest additions. Br J Pharmacol 141, 765-774, 2004. http://dx.doi.org/10.1038/sj.bjp.0705666
31. Dewey WL: Cannabinoid pharmacology. Pharmacol Rev 38, 151-178, 1986.
32. Di Marzo V: Manipulation of the endocannabinoid system by a general anaesthetic. Br J Pharmacol 139, 885-886, 2003. http://dx.doi.org/10.1038/sj.bjp.0705333
33. Di Marzo V: Targeting the endocannabinoid system: to enhance or reduce? Nat Rev Drug Discov 7, 438-455, 2008. http:// dx.doi.org/10.1038/nrd2553
34. Di Marzo V, Fontana A, Cadas H, Schinelli S, Cimino G, Schwartz JC, Piomelli D: Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 372, 686-691, 1994. http://dx.doi.org/10.1038/372686a0
35. Di Marzo V, Sepe N, De Petrocellis L, Berger A, Crozier G, Fride E, Mechoulam R: Trick or treat from food endocannabinoids? Nature 396, 636-637, 1998. http://dx.doi.org/10.1038/25267
36. Di S, Malcher-Lopes R, Halmos KC, Tasker JG: Nongenomic glucocorticoid inhibition via endocannabinoid release in the hypothalamus: a fast feedback mechanism. J Neurosci 23, 4850-4857, 2003.
37. Di S, Maxson MM, Franco A, Tasker JG: Glucocorticoids regulate glutamate and GABA synapse-specifc retrograde transmission via divergent nongenomic signaling pathways. J Neurosci 29, 393-401, 2009. http://dx.doi.org/10.1523/ JNEUROSCI.4546-08.2009
38. di Tomaso E, Beltramo M, Piomelli D: Brain cannabinoids in chocolate. Nature 382, 677-678, 1996. http://dx.doi. org/10.1038/382677a0
39. Du H, Chen X, Zhang J, Chen C: Inhibition of COX-2 expression by endocannabinoid 2-arachidonoylglycerol is mediated via PPAR-gamma. Br J Pharmacol 163, 1533-1549, 2011. http://dx.doi.org/10.1111/j.1476-5381.2011.01444.x
40. Duan Y, Zheng J, Nicholson RA: Inhibition of [3H]batrachotoxinin A-20alpha-benzoate binding to sodium channels and sodium channel function by endocannabinoids. Neurochem Int 52, 438-446, 2008. http://dx.doi.org/10.1016/j. neuint.2007.08.004
41. DuBiner H, Cooke D, Dirks M, Stewart WC, VanDenburgh AM, Felix C: Efcacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprost. Surv Ophthalmol 45 Suppl 4, S353-360, 2001. http://dx.doi.org/10.1016/S0039-6257(01)00212-0
42. Dunn AJ: Cytokine activation of the HPA axis. Ann N Y Acad Sci 917, 608-617, 2000. http://dx.doi.org/10.1111/j.1749-6632.2000. tb05426.x
43. Edgemond WS, Hillard CJ, Falck JR, Kearn CS, Campbell WB: Human platelets and polymorphonuclear leukocytes synthesize oxygenated derivatives of arachidonylethanolamide (anandamide): their afnities for cannabinoid receptors and pathways of inactivation. Mol Pharmacol 54, 180-188, 1998.
44. Elfag K, Finer N, Rossner S: Who will lose weight on sibutramine and orlistat? Psychological correlates for treatment success. Diabetes Obes Metab 10, 498-505, 2008. http://dx.doi.org/10.1111/j.1463-1326.2007.00740.x
45. Ellis J, Pediani JD, Canals M, Milasta S, Milligan G: Orexin-1 receptor-cannabinoid CB1 receptor heterodimerization results in both ligand-dependent and -independent coordinated alterations of receptor localization and function. J Biol Chem 281, 38812-38824, 2006. http://dx.doi.org/10.1074/jbc.M602494200
46. Farrell EK, Merkler DJ: Biosynthesis, degradation and pharmacological importance of the fatty acid amides. Drug Discov Today 13, 558-568, 2008. http://dx.doi.org/10.1016/j.drudis.2008.02.006
47. Felder CC, Joyce KE, Briley EM, Mansouri J, Mackie K, Blond O, Lai Y, Ma AL, Mitchell RL: Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol 48, 443-450, 1995.
48. Ferrer B, Bermudez-Silva FJ, Bilbao A, Alvarez-Jaimes L, Sanchez-Vera I, Giufrida A, Serrano A, Baixeras E, Khaturia S, Navarro M, Parsons LH, Piomelli D, Rodriguez de Fonseca F: Regulation of brain anandamide by acute administration of ethanol. Biochem J 404, 97-104, 2007. http://dx.doi.org/10.1042/BJ20061898
49. Finn DP: Endocannabinoid-mediated modulation of stress responses: physiological and pathophysiological signifcance. Immunobiology 215, 629-646, 2009. http://dx.doi.org/10.1016/j.imbio.2009.05.011
50. Fisar Z: Phytocannabinoids and endocannabinoids. Curr Drug Abuse Rev 2, 51-75, 2009. http://dx.doi. org/10.2174/1874473710902010051
51. Fowler CJ, Jacobsson SO: Cellular transport of anandamide, 2-arachidonoylglycerol and palmitoylethanolamide--targets for drug development? Prostaglandins Leukot Essent Fatty Acids 66, 193-200, 2002. http://dx.doi.org/10.1054/ plef.2001.0357
52. Fu J, Gaetani S, Oveisi F, Lo Verme J, Serrano A, Rodriguez De Fonseca F, Rosengarth A, Luecke H, Di Giacomo B, Tarzia G, Piomelli D: Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature 425, 90-93, 2003. http://dx.doi.org/10.1038/nature01921
53. Furuyashiki T, Narumiya S: Stress responses: the contribution of prostaglandin E(2) and its receptors. Nat Rev Endocrinol 7, 163-175, 2011. http://dx.doi.org/10.1038/nrendo.2010.194
54. Gaetani S, Oveisi F, Piomelli D: Modulation of meal pattern in the rat by the anorexic lipid mediator oleoylethanolamide. Neuropsychopharmacology 28, 1311-1316, 2003. http://dx.doi.org/10.1038/sj.npp.1300166
55. Gillum MP, Zhang D, Zhang XM, Erion DM, Jamison RA, Choi C, Dong J, Shanabrough M, Duenas HR, Frederick DW, Hsiao JJ, Horvath TL, Lo CM, Tso P, Cline GW, Shulman GI: N-acylphosphatidylethanolamine, a gutderived circulating factor induced by fat ingestion, inhibits food intake. Cell 135, 813-824, 2008. http://dx.doi. org/10.1016/j.cell.2008.10.043
56. Giufrida A, Parsons LH, Kerr TM, Rodriguez de Fonseca F, Navarro M, Piomelli D: Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat Neurosci 2, 358-563, 1999. http://dx.doi.org/10.1038/7268
57. Gomes I, Jordan BA, Gupta A, Rios C, Trapaidze N, Devi LA: G protein coupled receptor dimerization: implications in modulating receptor function. J Mol Med (Berl) 79, 226-242, 2001. http://dx.doi.org/10.1007/s001090100219
58. Gong J P, Onaivi ES, Ishiguro H, Liu QR, Tagliaferro PA, Brusco A, Uhl GR: Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain Res 1071, 10-23, 2006. http://dx.doi.org/10.1016/j.brainres.2005.11.035
59. Gonzalez S, Valenti M, de Miguel R, Fezza F, Fernandez-Ruiz J, Di Marzo V, Ramos JA: Changes in endocannabinoid contents in reward-related brain regions of alcohol-exposed rats, and their possible relevance to alcohol relapse. Br J Pharmacol 143, 455-464, 2004. http://dx.doi.org/10.1038/sj.bjp.0705963
60. Haller J, Barna I, Barsvari B, Gyimesi Pelczer K, Yasar S, Panlilio LV, Goldberg S: Interactions between environmental aversiveness and the anxiolytic effects of enhanced cannabinoid signaling by FAAH inhibition in rats. Psychopharmacology (Berl) 204, 607-616, 2009. http://dx.doi.org/10.1007/s00213-009-1494-7
61. Haller J, Varga B, Ledent C, Barna I, Freund TF: Context-dependent effects of CB1 cannabinoid gene disruption on anxiety-like and social behaviour in mice. Eur J Neurosci 19, 1906-1912, 2004. http://dx.doi.org/10.1111/j.14609568.2004.03293.x
62. Hampson AJ, Hill WA, Zan-Phillips M, Makriyannis A, Leung E, Eglen RM, Bornheim LM: Anandamide hydroxylation by brain lipoxygenase:metabolite structures and potencies at the cannabinoid receptor. Biochim Biophys Acta 1259, 173-179, 1995.
63. Hansen HS: Palmitoylethanolamide and other anandamide congeners. Proposed role in the diseased brain. Exp Neurol 224, 48-55, 2010. http://dx.doi.org/10.1016/j.expneurol.2010.03.022
64. Hansen HS, Diep TA: N-acylethanolamines, anandamide and food intake. Biochem Pharmacol 78, 553-560, 2009. http:// dx.doi.org/10.1016/j.bcp.2009.04.024
65. Hansen SL, Nielsen AH, Knudsen KE, Artmann A, Petersen G, Kristiansen U, Hansen SH, Hansen HS: Ketogenic diet is antiepileptogenic in pentylenetetrazole kindled mice and decrease levels of N-acylethanolamines in hippocampus. Neurochem Int 54, 199-204, 2009. http://dx.doi.org/10.1016/j.neuint.2008.10.012
66. Hanus L, Gopher A, Almog S, Mechoulam R: Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor. J Med Chem 36, 3032-3034, 1993. http://dx.doi.org/10.1021/jm00072a026
67. Harrold JA, Elliott JC, King PJ, Widdowson PS, Williams G: Down-regulation of cannabinoid-1 (CB-1) receptors in specific extrahypothalamic regions of rats with dietary obesity: a role for endogenous cannabinoids in driving appetite for palatable food? Brain Res 952, 232-238, 2002. http://dx.doi.org/10.1016/S0006-8993(02)03245-6
68. Hayase T: Nicotine (NC)-induced "depressive"behavioral symptoms and effects of antidepressants including cannabinoids (CBs). J Toxicol Sci 33, 555-564, 2008. http://dx.doi.org/10.2131/jts.33.555
69. Hayase T, Yamamoto Y, Yamamoto K: Persistent anxiogenic effects of a single or repeated doses of cocaine and methamphetamine: interactions with endogenous cannabinoid receptor ligands. Behav Pharmacol 16, 395-404, 2005. http://dx.doi.org/10.1097/00008877-200509000-00012
70. Hill MN, Patel S, Carrier EJ, Rademacher DJ, Ormerod BK, Hillard CJ, Gorzalka BB: Downregulation of endocannabinoid signaling in the hippocampus following chronic unpredictable stress. Neuropsychopharmacology 30, 508-515, 2005. http://dx.doi.org/10.1038/sj.npp.1300601
71. Hill MN, Gorzalka BB: Te endocannabinoid system and the treatment of mood and anxiety disorders. CNS Neurol Disord Drug Targets 8, 451-458, 2009.
72. Hill MN, McLaughlin RJ, Bingham B, Shrestha L, Lee T T, Gray JM, Hillard CJ, Gorzalka BB, Viau V: Endogenous cannabinoid signaling is essential for stress adaptation. Proc Natl Acad Sci U S A 107, 9406-9411, 2010. http://dx.doi. org/10.1073/pnas.0914661107
73. Hill MN, Patel S, Campolongo P, Tasker JG, Wotjak CT, Bains JS: Functional interactions between stress and the endocannabinoid system: from synaptic signaling to behavioral output. J Neurosci 30, 14980-14986, 2011. http://dx.doi. org/10.1523/JNEUROSCI.4283-10.2010
74. Ho WS, Randall MD: Endothelium-dependent metabolism by endocannabinoid hydrolases and cyclooxygenases limits vasorelaxation to anandamide and 2-arachidonoylglycerol. Br J Pharmacol 150, 641-651, 2007. http://dx.doi. org/10.1038/sj.bjp.0707141
75. Hojo M, Sudo Y, Ando Y, Minami K, Takada M, Matsubara T, Kanaide M, Taniyama K, Sumikawa K, Uezono Y: muOpioid receptor forms a functional heterodimer with cannabinoid CB1 receptor: electrophysiological and FRET assay analysis. J Pharmacol Sci 108, 308-319, 2008. http://dx.doi.org/10.1254/jphs.08244FP
76. Hong S, Fan J, Kemmerer ES, Evans S, Li Y, Wiley JW: Reciprocal changes in vanilloid (TRPV1) and endocannabinoid (CB1) receptors contribute to visceral hyperalgesia in the water avoidance stressed rat. Gut 58, 202-210, 2009. http://dx.doi.org/10.1136/gut.2008.157594
77. Hong S, Zheng G, Wu X, Snider NT, Owyang C, Wiley JW: Corticosterone mediates reciprocal changes in CB 1 and TRPV1 receptors in primary sensory neurons in the chronically stressed rat. Gastroenterology 140, 627-637 e4, 2011.
78. Howlett AC: Cannabinoid receptor signaling. Handb Exp Pharmacol 53-79, 2005.
79. Howlett AC, Bidaut-Russell M, Devane WA, Melvin LS, Johnson MR, Herkenham M: Te cannabinoid receptor: biochemical, anatomical and behavioral characterization. Trends Neurosci 13, 420-423, 1990. http://dx.doi. org/10.1016/0166-2236(90)90124-S
80. Huang SM, Bisogno T, Trevisani M, Al-Hayani A, De Petrocellis L, Fezza F, Tognetto M, Petros TJ, Krey JF, Chu CJ, Miller JD, Davies SN, Geppetti P, Walker JM, Di Marzo V: An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc Natl Acad Sci U S A 99, 8400-8405, 2002. http://dx.doi. org/10.1073/pnas.122196999
81. Inui A: Oleylethanolamide: a lipid mediator involved in gut satiety mechanisms. J Gastroenterol Hepatol 19, 117, 2004. http://dx.doi.org/10.1111/j.1440-1746.2004.03197.x
82. Izzo AA, Coutts AA: Cannabinoids and the digestive tract. Handb Exp Pharmacol 573-598, 2005.
83. Izzo AA, Mascolo N, Capasso F: Te gastrointestinal pharmacology of cannabinoids. Curr Opin Pharmacol 1, 597-603, 2001. http://dx.doi.org/10.1016/S1471-4892(01)00102-3
84. Jara LJ, Navarro C, Medina G, Vera-Lastra O, Blanco F: Immune-neuroendocrine interactions and autoimmune diseases. Clin Dev Immunol 13, 109-123, 2006. http://dx.doi.org/10.1080/17402520600877059
85. Jarrahian A, Watts VJ, Barker EL: D2 dopamine receptors modulate Galpha-subunit coupling of the CB1 cannabinoid receptor. J Pharmacol Exp Ter 308, 880-886, 2004. http://dx.doi.org/10.1124/jpet.103.057620
86. Jung KM, Astarita G, Zhu C, Wallace M, Mackie K, Piomelli D: A key role for diacylglycerol lipase-alpha in metabotropic glutamate receptor-dependent endocannabinoid mobilization. Mol Pharmacol 72, 612-621, 2007. http://dx.doi. org/10.1124/mol.107.037796
87. Jung KM, Mangieri R, Stapleton C, Kim J, Fegley D, Wallace M, Mackie K, Piomelli D: Stimulation of endocannabinoid formation in brain slice cultures through activation of group I metabotropic glutamate receptors. Mol Pharmacol 68, 1196-1202, 2005. http://dx.doi.org/10.1124/mol.105.013961
88. Karlsson M, Contreras JA, Hellman U, Tornqvist H, Holm C: cDNA cloning, tissue distribution, and identifcation of the catalytic triad of monoglyceride lipase. Evolutionary relationship to esterases, lysophospholipases, and haloperoxidases. J Biol Chem 272, 27218-27223, 1997. http://dx.doi.org/10.1074/jbc.272.43.27218
89. Katayama K, Ueda N, Kurahashi Y, Suzuki H, Yamamoto S, Kato I: Distribution of anandamide amidohydrolase in rat tissues with special reference to small intestine. Biochim Biophys Acta 1347, 212-218, 1997.
90. Katona I, Freund TF: Endocannabinoid signaling as a synaptic circuit breaker in neurological disease. Nat Med 14, 923-930, 2008. http://dx.doi.org/10.1038/nm.f.1869
91. Kim do Y, Rho JM: Te ketogenic diet and epilepsy. Curr Opin Clin Nutr Metab Care 11, 113-120, 2008. http://dx.doi. org/10.1097/MCO.0b013e3282f44c06
92. Kinsey SG, O'Neal ST, Long JZ, Cravatt BF, Lichtman AH: Inhibition of endocannabinoid catabolic enzymes elicits anxiolytic-like effects in the marble burying assay. Pharmacol Biochem Behav 98, 21-27, 2011. http://dx.doi. org/10.1016/j.pbb.2010.12.002
93. Kiortsis DN, Tsouli S, Filippatos TD, Konitsiotis S, Elisaf MS: Effects of sibutramine and orlistat on mood in obese and overweight subjects: a randomised study. Nutr Metab Cardiovasc Dis 18, 207-210, 2008. http://dx.doi. org/10.1016/j.numecd.2006.10.003
94. Kirkham TC, Williams CM, Fezza F, Di Marzo V: Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br J Pharmacol 136, 550-557, 2002. http://dx.doi.org/10.1038/sj.bjp.0704767
95. Kozak KR, Crews BC, Ray JL, Tai HH, Morrow JD, Marnett LJ: Metabolism of prostaglandin glycerol esters and prostaglandin ethanolamides in vitro and in vivo. J Biol Chem 276, 36993-36998, 2001. http://dx.doi.org/10.1074/ jbc.M105854200
96. Lauckner JE, Jensen JB, Chen HY, Lu HC, Hille B, Mackie K: GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc Natl Acad Sci U S A 105, 2699-2704, 2008. http://dx.doi.org/10.1073/ pnas.0711278105
97. Leggett JD, Aspley S, Beckett SR, D'Antona AM, Kendall DA: Oleamide is a selective endogenous agonist of rat and human CB1 cannabinoid receptors. Br J Pharmacol 141, 253-262, 2004. http://dx.doi.org/10.1038/sj.bjp.0705607
98. Lemberger T, Saladin R, Vazquez M, Assimacopoulos F, Staels B, Desvergne B, Wahli W, Auwerx J: Expression of the peroxisome proliferator-activated receptor alpha gene is stimulated by stress and follows a diurnal rhythm. J Biol Chem 271, 1764-1769, 1996. http://dx.doi.org/10.1074/jbc.271.3.1764
99. Leonard BE: Te immune system, depression and the action of antidepressants. Prog Neuropsychopharmacol Biol Psychiatry 25, 767-780, 2001. http://dx.doi.org/10.1016/S0278-5846(01)00155-5
100. Lichtman AH, Hawkins EG, Grifn G, Cravatt BF: Pharmacological activity of fatty acid amides is regulated, but not mediated, by fatty acid amide hydrolase in vivo. J Pharmacol Exp Ter 302, 73-79, 2002. http://dx.doi.org/10.1124/ jpet.302.1.73
101. Lo Verme J, Fu J, Astarita G, La Rana G, Russo R, Calignano A, Piomelli D: Te nuclear receptor peroxisome proliferatoractivated receptor-alpha mediates the anti-infammatory actions of palmitoylethanolamide. Mol Pharmacol 67, 15-19, 2005a. http://dx.doi.org/10.1124/mol.104.006353
102. LoVerme J, La Rana G, Russo R, Calignano A, Piomelli D: Te search for the palmitoylethanolamide receptor. Life Sci 77, 1685-1698, 2005b. http://dx.doi.org/10.1016/j.lfs.2005.05.012
103. Long JZ, Li W, Booker L, Burston JJ, Kinsey SG, Schlosburg JE, Pavon FJ, Serrano AM, Selley DE, Parsons LH, Lichtman AH, Cravatt BF: Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nat Chem Biol 5, 37-44, 2009. http://dx.doi.org/10.1038/nchembio.129
104. Lovinger DM: Presynaptic modulation by endocannabinoids. Handb Exp Pharmacol 435-477, 2008. Lutz B: Endocannabinoid signals in the control of emotion. Curr Opin Pharmacol 9, 46-52, 2009. http://dx.doi.org/10.1016/j.coph.2008.12.001
105. Maccarrone M, Cartoni A, Parolaro D, Margonelli A, Massi P, Bari M, Battista N, Finazzi-Agro A: Cannabimimetic activity, binding, and degradation of stearoylethanolamide within the mouse central nervous system. Mol Cell Neurosci 21, 126-140, 2002. http://dx.doi.org/10.1006/mcne.2002.1164
106. Mackie K: Cannabinoid receptor homoand heterodimerization. Life Sci 77, 1667-1673, 2005. http://dx.doi.org/10.1016/j.lfs.2005.05.011
107. Mackie K, Stella N: Cannabinoid receptors and endocannabinoids: evidence for new players. AAPS J 8, E298-306,2006.
108. Makara JK, Mor M, Fegley D, Szabo SI, Kathuria S, Astarita G, Duranti A, Tontini A, Tarzia G, Rivara S, Freund TF, Piomelli D: Selective inhibition of 2-AG hydrolysis enhances endocannabinoid signaling in hippocampus. Nat Neurosci 8, 1139-1141, 2005. http://dx.doi.org/10.1038/nn1521
109. Marcellino D, Carriba P, Filip M, Borgkvist A, Frankowska M, Bellido I, Tanganelli S, Muller CE, Fisone G, Lluis C, Agnati LF, Franco R, Fuxe K: Antagonistic cannabinoid CB1/dopamine D2 receptor interactions in striatal CB1/D2 heteromers. A combined neurochemical and behavioral analysis. Neuropharmacology 54, 815-823, 2008. http://dx.doi.org/10.1016/j.neuropharm.2007.12.011
110. Marco EM, Viveros MP: Te critical role of the endocannabinoid system in emotional homeostasis: avoiding excess and defciencies. Mini Rev Med Chem 9, 1407-1415, 2009. http://dx.doi.org/10.2174/138955709789957468
111. Martin M, Ledent C, Parmentier M, Maldonado R, Valverde O: Involvement of CB1 cannabinoid receptors in emotional behaviour. Psychopharmacology (Berl) 159, 379-387, 2002. http://dx.doi.org/10.1007/s00213-001-0946-5
112. Martinez-Vargas M, Murillo-Rodriguez E, Gonzalez-Rivera R, Landa A, Mendez-Diaz M, Prospro-Garcia O, Navarro L: Sleep modulates cannabinoid receptor 1 expression in the pons of rats. Neuroscience 117, 197-201, 2003. http://dx.doi.org/10.1016/S0306-4522(02)00820-5
113. Massi P, Valenti M, Bolognini D, Parolaro D: Expression and function of the endocannabinoid system in glial cells. Curr Pharm Des 14, 2289-2298, 2008. http://dx.doi.org/10.2174/138161208785740135
114. Matias I, Di Marzo V: Endocannabinoid synthesis and degradation, and their regulation in the framework of energy balance. J Endocrinol Invest 29, 15-26, 2006.
115. McAllister SD, Glass M: CB(1) and CB(2) receptor-mediated signalling: a focus on endocannabinoids. Prostaglandins Leukot Essent Fatty Acids 66, 161-171, 2002. http://dx.doi.org/10.1054/plef.2001.0344
116. McFarland MJ, Barker EL: Anandamide transport. Pharmacol Ter 104, 117-135, 2004. http://dx.doi.org/10.1016/j.pharmthera.2004.07.008
117. Mechoulam R, Fride E, Hanus L, Sheskin T, Bisogno T, Di Marzo V, Bayewitch M, Vogel Z: Anandamide may mediate sleep induction. Nature 389, 25-26, 1997. http://dx.doi.org/10.1038/37891
118. Meschler J P, Howlett AC: Signal transduction interactions between CB1 cannabinoid and dopamine receptors in the rat and monkey striatum. Neuropharmacology 40, 918-926, 2001. http://dx.doi.org/10.1016/S0028-3908(01)00012-0
119. Milligan G: Te role of dimerisation in the cellular trafcking of G-protein-coupled receptors. Curr Opin Pharmacol 10, 23-29, 2010. http://dx.doi.org/10.1016/j.coph.2009.09.010
120. Min R, Di Marzo V, Mansvelder HD: DAG lipase involvement in depolarization-induced suppression of inhibition: does endocannabinoid biosynthesis always meet the demand? Neuroscientist 16, 608-613, 2010. http://dx.doi.org/10.1177/1073858410373281
121. Moreira FA, Aguiar DC, Terzian AL, Guimaraes FS, Wotjak CT: Cannabinoid type 1 receptors and transient receptor potential vanilloid type 1 channels in fear and anxiety-two sides of one coin? Neuroscience 204, 186-192, 2012. http://dx.doi.org/10.1016/j.neuroscience.2011.08.046
122. Movahed P, Jonsson BA, Birnir B, Wingstrand JA, Jorgensen TD, Ermund A, Sterner O, Zygmunt PM, Hogestatt ED: Endogenous unsaturated C18 N-acylethanolamines are vanilloid receptor (TRPV1) agonists. J Biol Chem 280,38496-38504, 2005. http://dx.doi.org/10.1074/jbc.M507429200
123. Naidu PS, Varvel SA, Ahn K, Cravatt BF, Martin BR, Lichtman AH: Evaluation of fatty acid amide hydrolase inhibition in murine models of emotionality. Psychopharmacology (Berl) 192, 61-70, 2007. http://dx.doi.org/10.1007/s00213-006-0689-4
124. Nautiyal KM, Ribeiro AC, Pfaf DW, Silver R: Brain mast cells link the immune system to anxiety-like behavior. Proc Natl Acad Sci USA 105, 18053-18057, 2008. http://dx.doi.org/10.1073/pnas.0809479105
125. Navarro G, Carriba P, Gandia J, Ciruela F, Casado V, Cortes A, Mallol J, Canela EI, Lluis C, Franco R: Detection of heteromers formed by cannabinoid CB1, dopamine D2, and adenosine A2A G-protein-coupled receptors by combining bimolecular fuorescence complementation and bioluminescence energy transfer. ScientifcWorldJournal 8, 1088-1097, 2008. http://dx.doi.org/10.1100/tsw.2008.136
126. Nomura DK, Hudak CS, Ward AM, Burston JJ, Issa RS, Fisher KJ, Abood ME, Wiley JL, Lichtman AH, Casida JE: Monoacylglycerol lipase regulates 2-arachidonoylglycerol action and arachidonic acid levels. Bioorg Med Chem Lett 18, 5875-5878, 2008. http://dx.doi.org/10.1016/j.bmcl.2008.08.007
127. Okamoto Y, Morishita J, Tsuboi K, Tonai T, Ueda N: Molecular characterization of a phospholipase D generating anandamide and its congeners. J Biol Chem 279, 5298-5305, 2004. http://dx.doi.org/10.1074/jbc.M306642200
128. Olango WM, Roche M, Ford GK, Harhen B, Finn DP: Te endocannabinoid system in the rat dorsolateral periaqueductal grey mediates fear-conditioned analgesia and controls fear expression in the presence of nocicpetive tone. Br J Pharmacol 165, 2549-2560, 2012. http://dx.doi.org/10.1111/j.1476-5381.2011.01478.x
129. Onaivi ES, Ishiguro H, Gong JP, Patel S, Meozzi PA, Myers L, Perchuk A, Mora Z, Tagliaferro PA, Gardner E, Brusco A, Akinshola BE, Hope B, Lujilde J, Inada T, Iwasaki S, Macharia D, Teasenftz L, Arinami T, Uhl GR: Brain neuronal CB2 cannabinoid receptors in drug abuse and depression: from mice to human subjects. PLoS One 3, e1640, 2008.
130. Osei-Hyiaman D, DePetrillo M, Pacher P, Liu J, Radaeva S, Batkai S, Harvey-White J, Mackie K, Ofertaler L, Wang L, Kunos G: Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 115, 1298-1305, 2005.
131. Overton HA, Babbs AJ, Doel SM, Fyfe MC, Gardner LS, Grifn G, Jackson HC, Procter MJ, Rasamison CM, TangChristensen M, Widdowson PS, Williams GM, Reynet C: Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents. Cell Metab 3, 167-175, 2006. http://dx.doi.org/10.1016/j.cmet.2006.02.004
132. Pacher P, Batkai S, Kunos G: Te endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 58, 389-462, 2006. http://dx.doi.org/10.1124/pr.58.3.2
133. Pagotto U, Marsicano G, Cota D, Lutz B, Pasquali R: Te emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 27, 73-100, 2006. http://dx.doi.org/10.1210/er.2005-0009
134. Patel S, Roelke CT, Rademacher DJ, Cullinan WE, Hillard CJ: Endocannabinoid signaling negatively modulates stressinduced activation of the hypothalamic-pituitary-adrenal axis. Endocrinology 145, 5431-5438, 2004. http:// dx.doi.org/10.1210/en.2004-0638
135. Patel S, Carrier EJ, Ho WS, Rademacher DJ, Cunningham S, Reddy DS, Falck JR, Cravatt BF, Hillard CJ: Te postmortal accumulation of brain N-arachidonylethanolamine (anandamide) is dependent upon fatty acid amide hydrolase activity. J Lipid Res 46, 342-349, 2005. http://dx.doi.org/10.1194/jlr.M400377-JLR200
136. Patel S, Hillard CJ: Role of endocannabinoid signaling in anxiety and depression. Curr Top Behav Neurosci 1, 347-371, 2009. http://dx.doi.org/10.1007/978-3-540-88955-7_14
137. Paunescu H, Coman OA, Coman L, Ghita I, Georgescu SR, Draghia F, Fulga I: Cannabinoid system and cyclooxygenases inhibitors. J Med Life 4, 11-20, 2011.
138. Pertwee RG: Tolerance to the effect of delta1-tetrahydrocannabinol on corticosterone levels in mouse plasma produced by repeated administration of cannabis extract or delta1-tetrahydrocannabinol. Br J Pharmacol 51, 391-397, 1974.
139. Petrosino S, Di Marzo V: FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels. Curr Opin Investig Drugs 11, 51-62, 2010.
140. Pickel VM, Chan J, Kearn CS, Mackie K: Targeting dopamine D2 and cannabinoid-1 (CB1) receptors in rat nucleus accumbens. J Comp Neurol 495, 299-313, 2006. http://dx.doi.org/10.1002/cne.20881
141. Piomelli D: Te molecular logic of endocannabinoid signalling. Nat Rev Neurosci 4, 873-884, 2003. http://dx.doi. org/10.1038/nrn1247
142. Piomelli D, Tarzia G, Duranti A, Tontini A, Mor M, Compton TR, Dasse O, Monaghan EP, Parrott JA, Putman D: Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597). CNS Drug Rev 12, 21-38, 2006. http:// dx.doi.org/10.1111/j.1527-3458.2006.00021.x
143. Piomelli D, Astarita G, Rapaka R: A neuroscientist's guide to lipidomics. Nat Rev Neurosci 8, 743-754, 2007. http://dx.doi. org/10.1038/nrn2233
144. Porter AC, Sauer JM, Knierman MD, Becker GW, Berna MJ, Bao J, Nomikos GG, Carter P, Bymaster FP, Leese AB, Felder CC: Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J Pharmacol Exp Ter 301, 1020-1024, 2002. http://dx.doi.org/10.1124/jpet.301.3.1020
145. Prinster SC, Hague C, Hall RA: Heterodimerization of g protein-coupled receptors: specifcity and functional signifcance. Pharmacol Rev 57, 289-298, 2005. http://dx.doi.org/10.1124/pr.57.3.1
146. Ramwell P W, Shaw JE, Corey EJ, Andersen N: Biological activity of synthetic prostaglandins. Nature 221, 1251-1253, 1969. http://dx.doi.org/10.1038/2211251b0
147. Rao P, Knaus EE: Evolution of nonsteroidal anti-infammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond. J Pharm Pharm Sci 11, 81s-110s, 2008.
148. Riebe CJ, Wotjak CT: Endocannabinoids and stress. Stress 14, 384-397, 2011.
149. Rios C, Gomes I, Devi LA: mu opioid and CB1 cannabinoid receptor interactions: reciprocal inhibition of receptor signaling and neuritogenesis. Br J Pharmacol 148, 387-395, 2006. http://dx.doi.org/10.1038/sj.bjp.0706757
150. Roche M, Kelly J P, O' Driscoll M, Finn DP: Augmentation of endogenous cannabinoid tone modulates lipopolysaccharide-induced alterations in circulating cytokine levels in rats. Immunology 125, 263-271, 2008. http://dx.doi. org/10.1111/j.1365-2567.2008.02838.x
151. Rodriguez de Fonseca F, Navarro M, Gomez R, Escuredo L, Nava F, Fu J, Murillo-Rodriguez E, Giufrida A, Lo Verme J, Gaetani S, Kathuria S, Gall C, Piomelli D: An anorexic lipid mediator regulated by feeding. Nature 414, 209-212, 2001. http://dx.doi.org/10.1038/35102582
152. Rozenfeld R, Gupta A, Gagnidze K, Lim MP, Gomes I, Lee-Ramos D, Nieto N, Devi LA: AT1R-CBR heteromerization reveals a new mechanism for the pathogenic properties of angiotensin II. EMBO J 30, 2350-2363, 2011. http:// dx.doi.org/10.1038/emboj.2011.139
153. Ryberg E, Larsson N, Sjogren S, Hjorth S, Hermansson NO, Leonova J, Elebring T, Nilsson K, Drmota T, Greasley PJ: Te orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 152, 1092-1101, 2007. http://dx.doi. org/10.1038/sj.bjp.0707460
154. Sandoval JA, Huang ZH, Garrett DC, Gage DA, Chapman KD: N-acylphosphatidylethanolamine in dry and imbibing cottonseeds. Amounts, molecular species, and enzymatic synthesis. Plant Physiol 109, 269-275, 1995. http:// dx.doi.org/10.1104/pp.109.1.269
155. Schabitz WR, Giufrida A, Berger C, Aschof A, Schwaninger M, Schwab S, Piomelli D: Release of fatty acid amides in a patient with hemispheric stroke: a microdialysis study. Stroke 33, 2112-2114, 2002. http://dx.doi.org/10.1161/01. STR.0000023491.63693.18
156. Schmid HH, Schmid PC, Berdyshev EV: Cell signaling by endocannabinoids and their congeners: questions of selectivity and other challenges. Chem Phys Lipids 121, 111-134, 2002. http://dx.doi.org/10.1016/S0009-3084(02)001573
157. Schmid HH, Schmid PC, Natarajan V: N-acylated glycerophospholipids and their derivatives. Prog Lipid Res 29, 1-43, 1990. http://dx.doi.org/10.1016/0163-7827(90)90004-5
158. Sciolino NR, Zhou W, Hohmann AG: Enhancement of endocannabinoid signaling with JZL184, an inhibitor of the 2-arachidonoylglycerol hydrolyzing enzyme monoacylglycerol lipase, produces anxiolytic effects under conditions of high environmental aversiveness in rats. Pharmacol Res 64, 226-234, 2011. http://dx.doi.org/10.1016/j. phrs.2011.04.010
159. Shiratsuchi A, Ichiki M, Okamoto Y, Ueda N, Sugimoto N, Takuwa Y, Nakanishi Y: Inhibitory effect of N-palmitoylphosphatidylethanolamine on macrophage phagocytosis through inhibition of Rac1 and Cdc42. J Biochem 145, 43-50, 2009. http://dx.doi.org/10.1093/jb/mvn139
160. Shujaa N, Zadori ZS, Ronai AZ, Barna I, Mergl Z, Mozes MM, Gyires K: Analysis of the effect of neuropeptides and cannabinoids in gastric mucosal defense initiated centrally in the rat. J Physiol Pharmacol 60 Suppl 7, 93-100, 2009.
161. Simon GM, Cravatt BF: Characterization of mice lacking candidate N-acyl ethanolamine biosynthetic enzymes provides evidence for multiple pathways that contribute to endocannabinoid production in vivo. Mol Biosyst 6, 1411-1418, 2010. http://dx.doi.org/10.1039/c000237b
162. Smith PB, Compton DR, Welch SP, Razdan RK, Mechoulam R, Martin BR: Te pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J Pharmacol Exp Ter 270, 219-227, 1994.
163. Steiner MA, Marsicano G, Nestler EJ, Holsboer F, Lutz B, Wotjak CT: Antidepressant-like behavioral effects of impaired cannabinoid receptor type 1 signaling coincide with exaggerated corticosterone secretion in mice. Psychoneuroendocrinology 33, 54-67, 2008. http://dx.doi.org/10.1016/j.psyneuen.2007.09.008
164. Sugiura T, Kondo S, Kishimoto S, Miyashita T, Nakane S, Kodaka T, Suhara Y, Takayama H, Waku K: Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells. J Biol Chem 275, 605-612, 2000. http://dx.doi.org/10.1074/jbc.275.1.605
165. Sugiura T, Yoshinaga N, Waku K: Rapid generation of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand, in rat brain after decapitation. Neurosci Lett 297, 175-178, 2001. http://dx.doi.org/10.1016/S0304-3940(00)01691-8
166. Sugiura T, Kobayashi Y, Oka S, Waku K: Biosynthesis and degradation of anandamide and 2-arachidonoylglycerol and their possible physiological signifcance. Prostaglandins Leukot Essent Fatty Acids 66, 173-192, 2002. http://dx.doi.org/10.1054/plef.2001.0356
167. Sugiura T, Kishimoto S, Oka S, Gokoh M: Biochemistry, pharmacology and physiology of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand. Prog Lipid Res 45, 405-446, 2006. http://dx.doi.org/10.1016/j.plipres.2006.03.003
168. Sumislawski JJ, Ramikie TS, Patel S: Reversible gating of endocannabinoid plasticity in the amygdala by chronic stress: a potential role for monoacylglycerol lipase inhibition in the prevention of stress-induced behavioral adaptation. Neuropsychopharmacology 36, 2750-2761, 2011. http://dx.doi.org/10.1038/npp.2011.166
169. Sun Y, Bennett A: Cannabinoids: a new group of agonists of PPARs. PPAR Res 2007, 23513, 2007.
170. Sun Y, Alexander SP, Garle MJ, Gibson CL, Hewitt K, Murphy S P, Kendall DA, Bennett AJ: Cannabinoid activation of PPAR alpha; a novel neuroprotective mechanism. Br J Pharmacol 152, 734-743, 2007. http://dx.doi.org/10.1038/sj.bjp.0707478
171. Taber KH, Hurley RA: Endocannabinoids: stress, anxiety, and fear. J Neuropsychiatry Clin Neurosci 21, iv, 109-113, 2009.
172. Turk RF, Forney RB, King LJ, Ramachandran S: A method for extraction and chromatographic isolation, purifcation and identifcation of tetrahydrocannabinol and other compounds from marihuana. J Forensic Sci 14, 385-388, 1969.
173. Turu G, Varnai P, Gyombolai P, Szidonya L, Ofertaler L, Bagdy G, Kunos G, Hunyady L: Paracrine transactivation of the CB1 cannabinoid receptor by AT1 angiotensin and other Gq/11 protein-coupled receptors. J Biol Chem 284, 16914-16921, 2009. http://dx.doi.org/10.1074/jbc.M109.003681
174. Ueda N, Tsuboi K, Uyama T: Enzymological studies on the biosynthesis of N-acylethanolamines. Biochim Biophys Acta 1801, 1274-1285, 2010.
175. Ueda N, Yamamoto K, Yamamoto S, Tokunaga T, Shirakawa E, Shinkai H, Ogawa M, Sato T, Kudo I, Inoue K, et al.: Lipoxygenase-catalyzed oxygenation of arachidonylethanolamide, a cannabinoid receptor agonist. Biochim Biophys Acta 1254, 127-134, 1995.
176. Walter L, Dinh T, Stella N: ATP induces a rapid and pronounced increase in 2-arachidonoylglycerol production by astrocytes, a response limited by monoacylglycerol lipase. J Neurosci 24, 8068-8074, 2004. http://dx.doi.org/10.1523/JNEUROSCI.2419-04.2004
177. Wang J, Ueda N: Role of the endocannabinoid system in metabolic control. Curr Opin Nephrol Hypertens 17, 1-10, 2008. http://dx.doi.org/10.1097/MNH.0b013e3282f29071
178. Watanabe S, Doshi M, Hamazaki T: n-3 Polyunsaturated fatty acid (PUFA) defciency elevates and n-3 PUFA enrichment reduces brain 2-arachidonoylglycerol level in mice. Prostaglandins Leukot Essent Fatty Acids 69, 51-59, 2003. http://dx.doi.org/10.1016/S0952-3278(03)00056-5
179. Wei XY, Yang JY, Dong YX, Wu CF: Anxiolytic-like effects of oleamide in group-housed and socially isolated mice. Prog Neuropsychopharmacol Biol Psychiatry 31, 1189-1195, 2007. http://dx.doi.org/10.1016/j.pnpbp.2007.04.008
180. Wenger T, Moldrich G: Te role of endocannabinoids in the hypothalamic regulation of visceral function. Prostaglandins Leukot Essent Fatty Acids 66, 301-307, 2002. http://dx.doi.org/10.1054/plef.2001.0353
181. Witting A, Walter L, Wacker J, Moller T, Stella N: P2X7 receptors control 2-arachidonoylglycerol production by microglial cells. Proc Natl Acad Sci USA 101, 3214-3219, 2004. http://dx.doi.org/10.1073/pnas.0306707101
182. Wolf SA, Tauber S, Ullrich O: CNS immune surveillance and neuroinfammation: endocannabinoids keep control. Curr Pharm Des 14, 2266-2278, 2008. http://dx.doi.org/10.2174/138161208785740090
183. Wolf SA, Ullrich O: Endocannabinoids and the brain immune system: new neurones at the horizon? J Neuroendocrinol 20 Suppl 1, 15-19, 2008. http://dx.doi.org/10.1111/j.1365-2826.2008.01672.x
184. Woodward DF, Carling RW, Cornell CL, Fliri HG, Martos JL, Pettit SN, Liang Y, Wang JW: Te pharmacology and therapeutic relevance of endocannabinoid derived cyclo-oxygenase (COX)-2 products. Pharmacol Ter 120, 71-80, 2008. http://dx.doi.org/10.1016/j.pharmthera.2008.08.001
185. Zanettini C, Panlilio LV, Alicki M, Goldberg SR, Haller J, Yasar S: Effects of Endocannabinoid System Modulation on Cognitive and Emotional Behavior. Front Behav Neurosci 5, 57, 2011. http://dx.doi.org/10.3389/fnbeh.2011.00057
186. Zoppi S, Perez Nievas BG, Madrigal JL, Manzanares J, Leza JC, Garcia-Bueno B: Regulatory role of cannabinoid receptor 1 in stress-induced excitotoxicity and neuroinfammation. Neuropsychopharmacology 36, 805-818, 2011. http://dx.doi.org/10.1038/npp.2010.214